State Street Corp Vor Biopharma Inc. Transaction History

State Street Corp

$2.21 Trillion
Q1 2024

A detailed history of State Street Corp transactions in Vor Biopharma Inc. stock. As of the latest transaction made, State Street Corp holds 657,707 shares of VOR stock, worth $598,513. This represents 0.0% of its overall portfolio holdings.

Number of Shares

657,707

Previous 608,007 8.17%

Holding current value

$598,513

Previous $1.37 Million 13.89%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.8 - $2.85 $89,460 - $141,645	49,700 Added 8.17%	657,707 $1.56 Million
Q4 2023 Feb 14, 2024	BUY	$1.66 - $2.63 $3,486 - $5,523	2,100 Added 0.35%	608,007 $1.37 Million
Q3 2023 Nov 14, 2023	SELL	$2.1 - $3.35 $49,095 - $78,319	-23,379 Reduced 3.72%	605,907 $1.28 Million
Q2 2023 Aug 14, 2023	BUY	$3.09 - $5.33 $1.79 Million - $3.08 Million	578,173 Added 1131.17%	629,286 $1.94 Million
Q1 2023 May 15, 2023	BUY	$4.68 - $6.96 $5,616 - $8,352	1,200 Added 2.4%	51,113 $274,000

Q4 2022 Feb 14, 2023	BUY	$3.98 - $7.43 $34,626 - $64,641	8,700 Added 21.11%	49,913 $331,000
Q2 2022 Aug 15, 2022	SELL	$3.89 - $6.44 $940,847 - $1.56 Million	-241,863 Reduced 85.44%	41,213 $205,000
Q1 2022 May 16, 2022	BUY	$6.04 - $12.23 $108,061 - $218,806	17,891 Added 6.75%	283,076 $1.71 Million
Q4 2021 Feb 14, 2022	BUY	$11.32 - $18.02 $328,981 - $523,697	29,062 Added 12.31%	265,185 $3.08 Million
Q3 2021 Nov 15, 2021	BUY	$12.24 - $20.38 $420,076 - $699,441	34,320 Added 17.01%	236,123 $3.7 Million
Q2 2021 Aug 16, 2021	BUY	$18.65 - $38.78 $601,872 - $1.25 Million	32,272 Added 19.04%	201,803 $3.76 Million
Q1 2021 May 17, 2021	BUY	$30.96 - $54.08 $5.25 Million - $9.17 Million	169,531 New	169,531 $7.31 Million

Others Institutions Holding VOR

# of Institutions

Shares Held

29M

Call Options Held

1.8K

Put Options Held

100

View Full List

About Vor Biopharma Inc.

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $34.6M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

More about VOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Vor Biopharma Inc. Transaction History